<DOC>
	<DOCNO>NCT00000839</DOCNO>
	<brief_summary>To assess pharmacokinetics , safety , toxicity intravenous oral didanosine ( ddI ) administration third trimester pregnant woman HIV positive either intolerant resistant zidovudine ( AZT ) . To collect data infant toxicity follow maternal treatment ddI third trimester pregnancy . AZT may optimal antiretroviral agent pregnant woman require therapy HIV infection . Although ddI approve use HIV-infected adult old child , safety pharmacokinetics ddI pregnant woman yet determine .</brief_summary>
	<brief_title>A Phase I Trial Evaluate Didanosine ( ddI ) HIV-Infected Pregnant Women</brief_title>
	<detailed_description>AZT may optimal antiretroviral agent pregnant woman require therapy HIV infection . Although ddI approve use HIV-infected adult old child , safety pharmacokinetics ddI pregnant woman yet determine . Patients receive single IV dose ddI day 1 pharmacokinetics value determine . At least 48 hour 1 week IV dose , patient receive oral dose , oral pharmacokinetics obtain 8 hour . Oral ddI administer every 12 hour labor commences delivery , every 12 hour 6 week postpartum . During labor delivery , patient receive load dose ddI follow continuous infusion . Pharmacokinetics obtain infusion also 6 week postpartum . AS PER AMENDMENT 11/24/97 : Maternal IV pharmacokinetic study perform ddI IV formulation expire ( 11/30/97 ) . Maternal cord sample require regardless whether mother receive continuous IV ddI labor .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine . IV AZT labor . Patients must : HIV infection . CD4 count &gt; 50 &lt; 350 cells/mm3 . AZT intolerance resistance . Gestational age least 26 week 36 week . Consent guardian necessary . The father fetus must also provide consent available reasonable attempt make contact . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Multiple gestation . Current obstetrical complication , major anomaly , growth retardation , abnormal fluid level , fetal hydrops , placental abruption ( placenta previa allow ) . No access participate ACTU . Concurrent Medication : Excluded : Drugs might aggravate pancreatitis , steroid , isoniazid , parenteral pentamidine . Antiretrovirals ddI ( although IV AZT allow labor ) . Patients follow prior condition exclude : History stillbirth , neonatal loss , previous infant anomaly ( history preeclampsia preterm labor permit ) . History maternal medical complication include limited malabsorption syndrome , pancreatitis , neurological complication include grade 2 bad peripheral neuropathy , symptomatic cholelithiasis , prior active CMV disease require ganciclovir foscarnet . History poor medical compliance related access medical care . Prior Medication : Excluded : ddI within 24 hour prior study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Pregnancy Trimester , Third</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>